Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
160 patients with advanced HCC who attained CR (70 by mRECIST; 90 by RECIST v1.
I · Intervention 중재 / 시술
resection or liver transplantation, 6 (75%) achieved pathologic complete response, 2 in the CR-RECISTv1
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Extended ICI duration post-CR and selective conversion therapy may optimize outcomes. These findings redefine prognostic paradigms and underscore the need for biomarker-driven strategies to sustain remission.
[BACKGROUND] Immune checkpoint inhibitors (ICIs) have revolutionized advanced hepatocellular carcinoma (HCC) treatment, yet complete responses (CRs) remain rare, and their long-term outcomes are poorl
- p-value p=0.003
- p-value p=0.011
APA
Shao Y, Yuan J, et al. (2025). Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.. Frontiers in oncology, 15, 1687449. https://doi.org/10.3389/fonc.2025.1687449
MLA
Shao Y, et al.. "Imaging-defined complete response to immune checkpoint inhibitors predicts durable survival in advanced hepatocellular carcinoma.." Frontiers in oncology, vol. 15, 2025, pp. 1687449.
PMID
41755988 ↗
Abstract 한글 요약
[BACKGROUND] Immune checkpoint inhibitors (ICIs) have revolutionized advanced hepatocellular carcinoma (HCC) treatment, yet complete responses (CRs) remain rare, and their long-term outcomes are poorly characterized. This study evaluates clinical outcomes, pathologic correlates, and optimal management strategies for HCC patients achieving CR to ICI-based therapy.
[METHODS] We retrospectively analyzed 160 patients with advanced HCC who attained CR (70 by mRECIST; 90 by RECIST v1.1) following ICI therapy at four tertiary centers. Outcomes included recurrence-free survival (RFS), overall survival (OS), and pathologic validation of radiographic CR. Multivariable Cox models identified predictors of RFS.
[RESULTS] CRs occurred in 4.8% of treated patients. The cohort demonstrated exceptional survival, with 3-year OS and RFS rates of 86% and 55%, respectively. Among the 8 patients who underwent resection or liver transplantation, 6 (75%) achieved pathologic complete response, 2 in the CR-RECISTv1.1 group and 4 in the CR-mRECIST-only group, supporting imaging validity. Multivariable analysis revealed presence of macrovascular invasion (aHR 2.47, p=0.003) and presence of extrahepatic metastases (aHR 2.00, p=0.011) as independent risk factors for recurrence, while CR by RECIST v1.1 predicted improved RFS (aHR 0.62, p=0.015). Patients continuing ICI ≥6 months post-CR had superior 3-year RFS (81% vs. 55%, p=0.002). Of 11 patients undergoing curative conversion therapy (resection/transplantation/ablation), 92% survived at 3 years with 75% RFS.
[CONCLUSIONS] CR to ICI therapy, though uncommon, correlates with unprecedented survival in advanced HCC, even among high-risk subgroups. mRECIST-defined CR shows strong pathologic concordance, addressing concerns about anti-angiogenic confounders. Extended ICI duration post-CR and selective conversion therapy may optimize outcomes. These findings redefine prognostic paradigms and underscore the need for biomarker-driven strategies to sustain remission.
[METHODS] We retrospectively analyzed 160 patients with advanced HCC who attained CR (70 by mRECIST; 90 by RECIST v1.1) following ICI therapy at four tertiary centers. Outcomes included recurrence-free survival (RFS), overall survival (OS), and pathologic validation of radiographic CR. Multivariable Cox models identified predictors of RFS.
[RESULTS] CRs occurred in 4.8% of treated patients. The cohort demonstrated exceptional survival, with 3-year OS and RFS rates of 86% and 55%, respectively. Among the 8 patients who underwent resection or liver transplantation, 6 (75%) achieved pathologic complete response, 2 in the CR-RECISTv1.1 group and 4 in the CR-mRECIST-only group, supporting imaging validity. Multivariable analysis revealed presence of macrovascular invasion (aHR 2.47, p=0.003) and presence of extrahepatic metastases (aHR 2.00, p=0.011) as independent risk factors for recurrence, while CR by RECIST v1.1 predicted improved RFS (aHR 0.62, p=0.015). Patients continuing ICI ≥6 months post-CR had superior 3-year RFS (81% vs. 55%, p=0.002). Of 11 patients undergoing curative conversion therapy (resection/transplantation/ablation), 92% survived at 3 years with 75% RFS.
[CONCLUSIONS] CR to ICI therapy, though uncommon, correlates with unprecedented survival in advanced HCC, even among high-risk subgroups. mRECIST-defined CR shows strong pathologic concordance, addressing concerns about anti-angiogenic confounders. Extended ICI duration post-CR and selective conversion therapy may optimize outcomes. These findings redefine prognostic paradigms and underscore the need for biomarker-driven strategies to sustain remission.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features.
- Suppression LIF with 8-Gingerol blockades colorectal cancer tumorigenesis by reversing M2-type macrophage polarization.
- LDHA-Mediated H3K18 Lactylation Promotes the Glycolysis in Non-Small Cell Lung Cancer Through Targeting PTEN.
- Analysis of error profiles of indels and structural variants in deep-sequencing data.
- Endoscope-Assisted Nipple-Sparing Mastectomy With Immediate Implant Reconstruction: A Retrospective Study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Pathological Complete Response after Robot-Assisted Pulmonary Resection Following CDK4/6 Inhibitor-Combined Endocrine Therapy for Endobronchial Oligometastatic Breast Cancer: A Case Report.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.